Palisade Bio PALI
NASDAQ PALI
$1.43 +0.08 (+5.93%)
At close: Oct 1, 2026 · 4:00 PM EDT

Palisade Bio (PALI) Preferred Stock Liabilities (2020)

Updated

Palisade Bio (PALI) reported Preferred Stock Liabilities of $9.5 million for Q4 2020.

Analysis

Palisade Bio (PALI) Preferred Stock Liabilities (2020) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Palisade Bio 234.35 Mn -162.09 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 9.50 Mn
API Access

Palisade Bio Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=PALI&period=max&api_key=YOUR_API_KEY